Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01008852 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT01008852 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 210 participants.
The verdict
NCT01008852, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.
Interventions
- DRUG Placebo
- DRUG SBI-087
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01008852
The ClinicalTrials.gov registry entry for NCT01008852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01008852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01008852 about?
NCT01008852 is a clinical study titled "Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis". This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.
What is the current status of trial NCT01008852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2009-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01008852?
The interventions under investigation include: Placebo (DRUG), SBI-087 (DRUG).
Who is sponsoring clinical trial NCT01008852?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.